PHILADELPHIA, Sept. 3 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) announced today the launch of the RELENZA(R) (zanamivir) Inhalation Powder Pandemic ...

RESEARCH TRIANGLE PARK, N.C., Dec. 19 /PRNewswire/ -- GlaxoSmithKline (GSK) is prepared to respond to public health needs for RELENZA(R) (zanamivir) Inhalation Powder this flu season following a ...

Glaxo Wellcome Inc. is writing to inform you of important revisions to the safety labeling for Relenza (zanamivir for inhalation), which is approved for the treatment of uncomplicated acute ...